Zdrowie i gospodarka · 04/12/2013

FDA Releases Draft Guidance on Interim Product Reporting for Human Drug Compounding Outsourcing Facilities

The FDA has announced the availability of a draft guidance for industry on interim product reporting requirements for human drug compounding outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act, addressing new provisions from the Drug Quality and Security Act.